AstraZeneca and Abbott end license agreement for the development of Certriad AstraZeneca announced today that it has notified Abbott that it will discontinue the development of CERTRIAD (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on 22 January 2011.
AstraZeneca PLC appoints new Non-Executive Director AstraZeneca today announced that the Right Honourable Baroness Shriti Vadera is to join the Board of Directors as a Non-Executive Director, with effect from 1 January 2011. She will also become a member of the Board’s Audit Committee.
Monday, 6 December 2010
European Commission Approves Brilique™ (Ticagrelor Tablets) AstraZeneca announced today that the European Commission has granted marketing authorisation to BRILIQUE™ (ticagrelor tablets) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS). This decision follows the positive opinion from the Committee for Medicinal Products for Human Use on 23rd September and is applicable to the 27 Member States and the 3 European Economic Area countries of the European Union.
AstraZeneca commences review of strategic options for Astra Tech AstraZeneca today announced that it has formally commenced a review of its strategic options for Astra Tech. Astra Tech develops, manufactures and markets dental implants and healthcare (urological and surgical) products. AstraZeneca continues to evaluate all alternatives for value maximisation from this business and any final decision will only be made when the results of the review have concluded. During the period of this review, AstraZeneca remains committed to supporting Astra Tech's business, customers and stakeholders.
Friday, 5 November 2010
KOMBIGLYZE™ XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG).
Tuesday, 2 November 2010
US Appeal Court affirms preliminary injunction against Apotex in PULMICORT RESPULES patent litigation On 1 November 2010, the US Court of Appeals for the Federal Circuit affirmed the District Court’s issuance of a preliminary injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) in the US. The Preliminary Injunction issued by the District Court in May 2009 therefore remains in place. No trial date for the patent litigation has been set.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.